The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Maurer MF, Lewis KE, Kuijper JL, Ardourel D, Gudgeon CJ, Chandrasekaran S, Mudri SL, Kleist KN, Navas C, Wolfson MF, Rixon MW, Swanson R, Dillon SR, Levin SD, Kimbung YR, Akutsu M, Logan DT, Walse B, Swiderek KM, Peng SL.
Maurer MF, et al. Among authors: walse b.
Nat Commun. 2022 Apr 4;13(1):1790. doi: 10.1038/s41467-022-29286-5.
Nat Commun. 2022.
PMID: 35379805
Free PMC article.